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Abstracts / Pediatric Hematology Oncology Journal 1 (2016) S1eS33 S21Background: Acquired aplastic anemia (AA) is a haematological emer-
gency in children and we have gained enormous knowledge about the
pathogenesis and immune mediated self-destruction of stem cells and
immunosuppressive therapy. Due to its rarity, we have limited data of this
entity, especially, its course and outcome in resource limited countries.
Patientsandmethods: The case recordsof childrenwhohadbeendiagnosed
to have AA since 2002 at our centre were reviewed. The diagnosis of AAwas
made in children with pancytopenia without organomegaly and conﬁrmed
by hypocellular bone marrow showing decreased expression of all three
hematopoietic lineages. Clinical ﬁndings including dysmorphism, thumb
abnormalities, congenital malformations and skin hyperpigmentation were
noted down. Mitomycin C induced chromosomal instability to rule out Fan-
coni anaemia, Ham's test to look for paroxysmal nocturnal haemoglobinuria
and chromosomal analysis to look for complex karyotypic abnormalities seen
in myelodysplastic syndrome were documented in all patients.
After initial stabilization, the option of haematopoietic stem cell trans-
plantation (HSCT) was offered to all those who had matched related do-
nors. If not, immunosuppressive therapy was delivered within twomonths
from diagnosis after the child was infection free. A combination of 40mg/
kg/day of Horse derived antithymocyte globulin (ATGAM) and methyl-
prednisolone at 2 mg/kg/day were started for the ﬁrst 4 days through a
central venous catheter. Oral cyclosporine and G-CSF were started on the
ﬁfth day and since 2015 Eltrombopag was added to the IST regimen.
Revolade and GCSF were continued for about 8 to 12 weeks and cyclo-
sporine from 6 to 12 months. All patient received Voriconazole and
Acyclovir prophylaxis till neutrophil recovery to 1000.
Results: A total of 109 children had been diagnosed as AA, of whom, 42
had acquired AA. Themean age of childrenwith acquired AAwas 8.16 years
(2-15 yrs). Boys were twice more commonly affected (ratio M: F ¼ 2:1).
Details are listed in table 1.
Of the 41, 21 underwent HSCT as they had fully matched related donor and
20 children received IST. Of the 20 children who received ATG, 10 children
(70%) had complete remission in a median duration of 78 days. Two of the
three non responders were treated with second IST and all three succumbed
to the illness. One child developed acute myeloid leukaemia after achieving
partial remission and was salvaged with HSCT, and 1 more non responder
had an unrelated HSCT and is doing well. One child has suffered a relapse
after a durable remission of over 18 months off immunosuppression. The 21
children who have been transplanted have an overall survival rate of 77 %.
Conclusion: Immunosuppressive regimen including Horse ATGAM,
Methyl prednisolone, Cyclosporine, GCSF and Eltrombopag along with
adequate and meticulous supportive care including neutropenic care,
prompt infection management and the use of irradiated and leukode-
pleted blood products results in a 70% response rate and should be offered
to all children with aplastic anaemia with no matched family donor. The
addition of Elthrombopag has resulted in early recovery of all three cell
lines and must be added to the IST protocol in children.Table 1
Clinical features & treatment outcome in Pediatric Aplastic anemia, n¼41
S. No Parameter Results
1. Mean age at presentation 8.16 year
2. Severity at presentation
Severe 41%
Very severe 54%
3. Children required >20 transfusions
prior to presentation
31.7%
4. Karyotypic abnormalities
Partial trisomy 10,14 & Trisomy 7 1
Mitomycin-C rest Equivocal in 1
Negative in others
Ham's test Negative in all
5. Treatment
1. ATG group 20
Survival 16
Complete Response 14
Second IST 2 (expired)
Salvage BMT 2
2. BMT group 21
Survival 16
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IS SERUM FERRITIN A RELIABLE MARKER FOR EVALUATION OF
CARDIAC AND HEPATIC IRON OVERLOAD IN PATIENTS WITH b-
THALASSEMIA MAJOR?
Ankita Pandey, Arijita Chatterjee, Reshma Nevgi, Amit Jain, Prakruthi
Kaushik, Sujata Sharma, Ratna Sharma, Mamta Manglani.
Background: Regular packed red cell transfusions, which is the mainstay
of therapy in thalassemia major, leads to iron overload. This requires
frequent monitoring, thereby instituting appropriate treatment and pre-
venting its associated complications. Iron overload-induced cardiomyop-
athy is reversible if intensive chelation therapy is instituted on time. Early
detection of myocardial iron deposition is imperative to prevent cardiac
complications known with iron overload. Conventionally, serum ferritin
has been used to monitor iron overload in these children. But there have
been recent studies, which have shown that T2* MRI is a better tool for
cardiac and liver iron overload in comparison with serum ferritin. We
analyzed our data to verify this correlation in our patients.
Aims and objectives: To study the correlation between serum ferritin and
T2*MRI for assessment of cardiac and hepatic iron overload in patients of
b-Thalassemia Major.
Materials andmethods: It was a retrospective, cross sectional, descriptive
study which analyzed records of 52patients with transfusion dependent b-
Thalassemia major in the Thalassemia day care centre at our institution.
Inclusion Criteria: Children with transfusion dependent b-thalassemia
major above 6 years of age in whomserum ferritin and T2*MRI were per-
formed at least within 3 months of each other.
Exclusion criteria: Any child withHepatitis B, Hepatitis C and HIV
infection.
Methodology: Demographic data, serum ferritin during last 3 months and
T2*MRI results (which was taken as the gold standard for iron overload)
were retrieved from the records.Standard deﬁnitions of severity of iron
overload for liver and heart on T2* MRI were used for comparisons (Liver:
normal > 6.3ms, mild - 2.8-6.3ms, moderate - 1.4-2.7ms, severe <1.4ms,
Cardiac: normal >20ms, mild - 14 e 20ms, moderate - 10 e 14ms, severe
<10ms.).Statistical analysis was done using Fisher's Exact test and ANOVA
test.
Results: A total of 52 patients were enrolled in the study.Their ages
ranged from 6 years to 22, with a median of 8.5yrs .31 were males and 21
were females. On the basis of T2* MRI values, patients were divided into
none, mild, moderate and severe hepatic and cardiac iron overload. He-
patic iron overload in our patients was as follows: none e 5 (9.6%), mild e
14 (26.9%), moderate e 10 (19.2%), severe e 23 (44.2%) and cardiac iron
overload as follows: none e 36 (69.2%), mild e 12 (23.0%), moderate e 3
(5.7%), severe e 1 (1.9%). When correlating serum ferritin below and
above 2000 ng/ml with the severity of iron overload on T2*MRI, therewas
no signiﬁcant association between serum ferritin levels and degree of iron
overload in cardiac as well as liver MRI (p ¼ 0.92 for cardiac iron overload
and p ¼ 0.39 for liver iron overload).Our results also show that there was
no signiﬁcant correlation between serum ferritin and cardiac MRIﬁndings
(p ¼ 0.725) or between ferritin and hepatic MRI (p ¼ 0.910). Also no
signiﬁcant correlation was observed between cardiac and hepatic MRI
values (p ¼ 0.07).
Conclusion: The present study concludes that there is no correlation be-
tween serum ferritin level and T2*MRI for cardiac as well as liver iron
overload. Hence, serum ferritin should not be the sole marker for evalu-
ating iron overload. Also, cardiac and hepatic iron overload on T2* MRI did
not correlate with each other. This suggests that individual organ evalua-
tion by T2* MRI may be the way ahead for effective prevention of com-
plications by appropriate chelation.
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Background: Primary immunodeﬁciency disorders (PIDs) are an impor-
tant but under-diagnosed cause of childhood morbidity and mortality.
HSCT is the curative treatment for PIDs. Finding a matched donor is a
stumbling block. Moreover, presence of severe infections at the time of
transplants increases the transplant-related mortality (TRM. Poor infra-
structure in developing world adds to the Gordian knot. So, RIC HSCT has
been reported as a safer modality.
Objectives: To describe the feasibility and outcome of RIC HSCT for PIDs.
Methods: Twelve children with various PIDs, from August 2013 to August
2016 who underwent HSCT under our care were included. Clinical records
were analyzed retrospectively.
Results: Twelve children (SCID-2, DOCK-8 deﬁciency-1, Chediak-Higashi
Syndrome-1, WAS-3, HLH-2, GATA2 mutation-1 and CVID-1, HO-1 deﬁ-
ciency-1) with mean age 5.72 year underwent HSCT. Male: Female ratio
was 11:1. Mean follow-up 419 days (9 to 1209 days). Eight underwent
haploidentical HSCT three had matched sibling donor (MSD) HSCT, and
one had MUD HSCT. In seven T-cell replete haploidentical and one MUD
HSCT the conditioning was with serotherapy (Alemtuzumab-4 or Rabbit
Anti-Thymoglobulin-4) along with Fludarabine, Cyclophosphamide, Thio-
tepa and TBI in 5, Fludarabine and Treosulfan in 2 and Fludarabine and
Busulfan in 1. All received post transplant cyclophosphamide 50 mg/kg on
day 3 and 4 for GVHD prophylaxis along with tacrolimus and MMF. In one,
TCR alpha-beta/CD19 depleted haploidentical HSCT the conditioning was
Alemtuzumab, Fludarabine, Treosulfan and Thiotepa with no GVHD pro-
phylaxis. Two MSD were conditioned with Anti-Thymoglobulin, Fludar-
abine and Cyclophosphamide and GVHD prophylaxis was cyclosporine and
methotrexate and one MSD was given Alemtuzumaab, Fludarabine,
Cyclophosphamide and TBI with Tacrolimus and MMF for GVHD prophy-
laxis. Mean CD34+ cell dose was 14.24106/kg for 8 patients with PBSC
graft and 32.1106/kg for 4 patients who got bone marrow. Ten patients
engrafted and two died prior to engraftment with bacterial sepsis on day
+8 and day+14 respectively. Mean neutrophil engraftment was on 16.8 day.
One patient died with thrombotic microangiopathy on day+28. Eight
survivors are fully donor (>95%) and one had mixed chimerism (85%).
Acute GVHD grade I-II developed in 4 children. Chronic GVHD of skin
developed in two. CMV reactivation was seen in two and BCG reactivation
in two. Overall survival 75% and TRM 25%.
Conclusion: RIC HSCT constitutes a feasible option for PIDs in developing
world and gives a ray of hope for these patients.
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Abstract
Background/Objectives: Donor availability remains one of the major
challenges for performing hematopoetic stem cell transplantation (HSCT)
in the treatment of hematologic malignancies. Matched sibling or unre-
lated donor cannot be identiﬁed or mobilized in time for many patients.
HLA-haploidentical donor transplantation (HIDT) using Tcell replete grafts
and post-transplantation cyclophosphamide (PTCY) for control of allor-
eactivity has emerged as an important option for patients who lack a
donor. Post-transplant cyclophosphamide (PTCY) is not toxic to hemato-
poietic stem cells because of high expression of enzyme aldehyde dehy-
drogenase but it induces selective allodepletion by killing host and donor T
cells proliferating in response to donor and host cells, respectively. Thus,
PTCY decreases GvHD but doesnot effect GvL. We report here the feasi-
bility and outcome of HIDT in a developing world setting.
Designs/Methods: Six children with hematological malignancies and no
available matched donor underwent HIDT from Dec2013 to Sept2016. The
clinical records and investigation sheets were analyzed retrospectively.
Patient's follow-up ranged from Day+10 to Day+732 (Mean Day+278)
Results: Mean age was 4.88 year (1.6-9 years). M:F ¼ 3:3. All had hemato-
logical malignancies (High risk Acute myeloid leukemia-2, Relapsed acute
lymphoblastic leukemia-4) and all were in complete remission (CR) at thetime of transplant. Conditioning was Fludarabine (40mg/m2/day) from Day-
8 to day-5, Cyclophosphamide (14.5mg/kg/day) on Day-4 and Day-3, Thio-
tepa (8mg/kg/day) on Day-2 and TBI (2Gy) on Day-1. All patients received
haploidentical peripheral blood stem cells. Mean CD34+ cell dose was 12.7
106/kg/recipient weight. PTCY (50 mg/kg/day) was given on Day+3 and
Day+4. Tacrolimus and MMF were started from Day+5 for Graft-Vs-Host
disease (GvHD) prophylaxis. Supportive care along with Voriconazole and
Valacyclovir for antifungal and antiviral prophylaxis was given. Five patients
engrafted while one awaits engraftment (short follow-up). Mean neutrophil
engraftment was on 18.6 day. Immediate post-transplant period was un-
eventful. Only one patient had viral reactivation, who had Adenovirus
induced hemorrhagic cystitis on Day+44 which was successfully treated
with Cidofovir. Chimerism studies showed fully donor in all patients who
were post Day+100. One patient of Pre-B ALL relapsed on Day+406 of HIDT.
This patient was very difﬁcult to bring in remission even before the trans-
plant and is now being taken up for the next transplant. Acute GVHD was
not seen in any patient. Chronic GVHD of skin was seen in two patients
which was conservatively managed. All six patients are alive.
Conclusion: In hematological malignancies patients who have no
matched donor available, HIDT with PTCY constitutes a feasible and
effective option.
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Background: Haploidentical stem cell transplantation in children with
benign haematological disorders offers a unique opportunity to cure a
child who has no matched family donor. However, the associated chal-
lenges are different to conventional allograft making the options subop-
timal so far. Recent advances have made this procedure feasible in very
young children and we describe our experience in the use of this
technique.
Patients andmethods: The studywas conducted at the blood andmarrow
transplantation unit at Apollo Hospital, Chennai. Children aged up to 18
years who underwent haploidentical transplantation from 2002 to 2016
were included in the study.
Results: A total of 23 paediatric haploidentical stem cell transplantations
have been performed at our centre so far. Of these 16/23 (69.5%) have been
for benign disorders including Fanconi anaemia in 3, Haemophagocytic
LymphoHistiocytosis in 2, 1 with severe aplastic anaemia and 10 with
primary immunedeﬁciency disorders namely, severe combined immune-
deﬁciency in 6, 1 each with Wiskott Aldrich syndrome, Hyper IgM syn-
drome, MSMD and Adrenoleukodystrophy. The sources of stem cells were
from sibling and parent and bone marrow and peripheral blood in equal
numbers. Techniques of T depletion used were CD 34 selection in 1,
Campath in the bag in 1, TCR alpha/beta depletion 2, CD3/19 depletion in 1
and post transplant cyclophosphamide (PTCy) in 11 children.
In transplants where PTCy was used, conditioning included Fludarabine/
Treosulphan in primary immunedeﬁciency, Fludarabine/ Treosulphan/
single dose TBI 200cGy in HLH, Fludarabine/ Cyclophosphamide/ single
dose TBI 200cGy in Fanconi anaemia and severe aplastic anaemia. In the
child with ZAP70 mutation where TCR alpha/beta depletion was used,
conditioning regimen included Fludarabine/ Treosulphan/ Thiotepa/ ATG.
12/16 (75%) transplants resulted in engraftment by Day 16-21 post HSCT
with sustained complete chimerism. Hyper IgM syndrome and MSMD
were 2 conditions where primary rejection resulted in autologous recon-
stitution. Acute skin and gut GVHD of grade 2-3 was noted in 5/16 (31%)
which was responsive to steroids. Chronic skin and mouth GVHD has been
noted in 1 child. CMV reactivation was noted in 5/16 (31%) children
wherein 4 children achieved negative CMV copies on treatment with
Valganciclovir.
Mortality among this group of patients was found to be 6/16 (37.5%). In the
PTCy group, 3 children died of aspergillosis, severe ARDS and ruptured
peliosis hepatis respectively. Campath use resulted in refractory CMV
